Zacks: Brokerages Anticipate Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to Post -$0.09 Earnings Per Share
Analysts forecast that Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) will post earnings of ($0.09) per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Conatus Pharmaceuticals’ earnings, with estimates ranging from ($0.27) to $0.13. Conatus Pharmaceuticals posted earnings per share of ($0.30) during the same quarter last year, which would indicate a positive year over year growth rate of 70%. The business is scheduled to issue its next earnings report on Wednesday, August 2nd.
Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.20. The company had revenue of $7 million for the quarter, compared to analyst estimates of $5.88 million. During the same period in the prior year, the company posted ($0.35) EPS.
CNAT has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Conatus Pharmaceuticals in a report on Friday, March 17th. ValuEngine upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 24th. Aegis reiterated a “buy” rating and issued a $11.00 price objective on shares of Conatus Pharmaceuticals in a research note on Thursday, March 16th. Stifel Nicolaus reiterated a “buy” rating and issued a $9.00 price objective (up previously from $7.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, March 16th. Finally, FBR & Co reiterated an “outperform” rating and issued a $16.00 price objective on shares of Conatus Pharmaceuticals in a research note on Wednesday, March 15th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $13.25.
Shares of Conatus Pharmaceuticals (CNAT) traded down 1.13% on Monday, hitting $6.13. 615,023 shares of the stock were exchanged. The company has a 50-day moving average price of $5.22 and a 200-day moving average price of $5.27. Conatus Pharmaceuticals has a one year low of $1.45 and a one year high of $9.40. The firm’s market capitalization is $160.42 million.
Large investors have recently bought and sold shares of the company. Courage Capital Management LLC raised its stake in Conatus Pharmaceuticals by 25.0% in the first quarter. Courage Capital Management LLC now owns 125,000 shares of the biotechnology company’s stock worth $721,000 after buying an additional 25,000 shares during the last quarter. Renaissance Technologies LLC raised its stake in Conatus Pharmaceuticals by 28.1% in the first quarter. Renaissance Technologies LLC now owns 235,290 shares of the biotechnology company’s stock worth $1,358,000 after buying an additional 51,590 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Conatus Pharmaceuticals by 2.1% in the first quarter. Bank of New York Mellon Corp now owns 80,310 shares of the biotechnology company’s stock worth $464,000 after buying an additional 1,655 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in Conatus Pharmaceuticals during the first quarter worth $854,000. Finally, Nationwide Fund Advisors acquired a new stake in Conatus Pharmaceuticals during the first quarter worth $413,000. 18.76% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/07/16/zacks-brokerages-anticipate-conatus-pharmaceuticals-inc-nasdaqcnat-to-post-0-09-earnings-per-share-updated.html.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.